Motif Bio Share Discussion Threads

[bookbroker] 26/1/2017 09:41

Volatile today!

[bookbroker] 25/1/2017 09:45

Nice little rise today, I'd just love to see it do a 10/20% uplift!

[stealive] 25/1/2017 08:50

There's a bit more talk on twitter about this share

[runwaypaul] 25/1/2017 07:27

yes ive seen it before.still, atleast someones got it reprinted to try and kick the price .last time it didn't seem to have any effect.maybe they thought itd work better now some of the placing stocck has gone.gl

[waterloo01] 24/1/2017 17:28

Old I think but has today's date?

[adorling] 24/1/2017 06:44

MTFB closed up 4.8% on Nasdaq last night.

[patviera] 23/1/2017 17:14

Well done WaterlooPrefer this to summ

[waterloo01] 23/1/2017 15:58

I note Motif are presenting here. I've added of late.

12:25 Panel III – Anti Bacterial/microbiome
Moderator: Sarah Haywood, CEO, MedCity
Panel:
• Richard Mason, Head of J&J Innovation, London, J&J
• Graham Lumsden, CEO, Motif Bio
• Neil Murray, CEO, Redx
• Glyn Edwards, CEO, Summit

[adorling] 23/1/2017 15:34

The MTFB ADS's up over 6% on Nasdaq. Beginning to look good on both sides of the Atlantic!

[timbo003] 23/1/2017 09:49

That's a very bullish forecast from Zeus on the Voxmarket podcast

Zeus risk adjusted target is now 107p/share

There's another interview with Garry Waanders that appeared this morning on Directors talk:

[bookbroker] 23/1/2017 09:26

A good start to the week, i get the feeling there is value in this stock gauging the progress it has made with its drug development programme, and funding that is secured for the foreseeable future!

[vatnabrekk] 20/1/2017 22:03

Just listened to the podcast. 2017 could be an exciting year.

[adorling] 20/1/2017 15:09

Link to Dr Gary Wanders Podcast.

[ohisay] 20/1/2017 14:46

I'm in - seems a worthwhile initial punt.

[adorling] 20/1/2017 14:25

Very persistent buying today and good interview with Dr Gary Wanders (Zeus Capital) on MTFB by Justin Waite Vox Markets Podcast (No689). Target price 107p risk adjusted! That would be a nice 4-bagger from here and even higher if the REVIVE-1 trial results meet the agreed FDA protocol end points on read out in Q2.

[timbo003] 20/1/2017 10:46

There's a new research note available for download from Shard Capital here:

[small crow] 18/1/2017 12:21

Feel free.

[patviera] 17/1/2017 21:02

Timbo This is different league to ValSwitch!!

[timbo003] 17/1/2017 18:13

>>>>hoggar,

Alas Iclaprim cannot combat flu viruses (it is an antibiotic not an anti viral), although (in theory) it could help combat secondary bacterial infections in the respiratory tract that often occur during the later stages of a virally induced flu.

[2bluelynn] 17/1/2017 17:13

Big pod cast on Vox markets .....Justine Waite (share pickers dot com )He has a lot of followers and has done a great blog on this stock thus the rise I reckon . Have a listen

[runwaypaul] 17/1/2017 12:48

perhaps if the anal inspectors over on lse took a min to stop counting how many hairs are protruding from their backsides and looked up, they might notice the price is actually up.

[hoggar] 13/1/2017 19:19

It's quite remarkable how this stock is NOT performing given the global struggle to find effective antibiotics to combat more efficient virus's. According to many sources a global pandemic on the scale of 1918 Spanish flu outbreak is imminent. That flu outbreak alone killed 18 million people yet we still ignore the obvious. The planet is over crowded and we do not have the means to fight a serious resistant virus.

[vulgaris] 09/1/2017 16:07

This week (from 9 Jan) includes the 35th JPM Morgan Annual Healthcare / Anti-Infectives Partnering meeting.

Reasonable to expect (as with all medical conferences) a degree of noise in the area.

[tromso1] 09/1/2017 15:44

27:34

"So I think at the minimum we are anticipating several hundred million dollars worth of peak year revenue for Iclaprim once we come to market"